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Summary As the diagnostic assessment of the different forms of interstitial lung
disease (ILD) is similar, this study aims to compare age, sex, the functional and
broncho-alveolar lavage fluid (BALF) findings at diagnosis between the different
forms of ILDs. In addition we want to determine which of these variables determine
survival. We evaluated 315 patients (176 males and 139 females) in whom the
diagnosis was made of sarcoidosis (n ¼ 87), ILD due to connective tissue disease
(n ¼ 56), hypersensitivity pneumonitis (n ¼ 50), idiopathic pulmonary fibrosis (IPF)
(n ¼ 64), other forms of idiopathic interstitial pneumonia (n ¼ 29) or ILD due to an
undefined form of fibrosis (n ¼ 29). We analysed the role on outcome of type of
disease, gender, age at diagnosis, type of cells in BALF, FVC and DLCO. In a Kaplan–
Meier analysis IPF has the worst outcome in comparison with other types of ILDs. A
Cox regression analysis showed that type of ILD, FVC, age at diagnosis and % of
macrophages in BALF predict outcome of patients affected by ILD.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Interstitial lung diseases (ILD) represent a very
large group of more than 200 different entities with
an estimated prevalence of 74.1 per 105 and
incidence of 28.8 105 per year.1,2
The diagnostic assessment of the different forms
of ILD is similar and is based on findings perceived
on lung function, laboratory, chest-X-ray, high-
resolution computed tomography, broncho-alveolar
lavage fluid (BALF) and histology. Good descriptions
on the assessment are available for sarcoidosis,
hypersensitivity pneumonitis, idiopathic pulmonary
fibrosis (IPF) and ILD due to connective tissue
disease. Furthermore for IPF, the predictive value
of findings at diagnosis3 and of the characteristics
on lung biopsy has been demonstrated.4 However,
to the best of our knowledge no comparisons of
possible determinants in the 6 most common forms
of ILD has been published.
Clinically the different ILD’s have rather similar
presentations with increasing shortness of breath
and widespread shadowing on the chest radio-
graph.5 As the diagnostic assessment of the
different forms of ILD is similar, the aim of this
study was to compare the characteristics of the
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different variables measured at diagnosis of the 6
most common forms of ILD entities and to deter-
mine the prognostic value of these variables on
outcome.
Methods
Subjects
Three hundred and fifteen patients with sarcoidosis
(SARC), IPF, other forms of idiopathic interstitial
pneumonia (IIP), lung fibrosis due to connective
tissue disease (CTD), hypersensitivity pneumonitis
(HP) and undefined forms of lung fibrosis who
attended the department of respiratory medicine
of our hospital between 1990 and 1999 are studied.
Only newly diagnosed ILD are presented in this
study. These ILD-patients are registered in the
framework of our prospective registration pro-
gramme of ILD in Flanders,6,7 which was approved
by the local Ethical Committee. In this registration
programme a standardised protocol was used for
diagnostic assessment, therapy and follow-up.
Diagnostic criteria
The diagnosis of IIP and IPF is based on criteria of
the ATS-ERS consensus statements.8,9 Our patholo-
gist (E.V.) re-assessed the biopsies in view of the
most recent classificationof the IIP.9
The diagnosis of sarcoidosis is based on a
compatible clinical picture of multi-organ involve-
ment, histologic demonstration of non-caseating
granulomas, and exclusion of other diseases cap-
able of producing a similar histologic or clinical
picture. If clinical, broncho-alveolar lavage and/or
radiological features alone are diagnostic for
sarcoidosis, no biopsy is performed.10
All patients with connective tissue disease have a
restrictive lung function defect (defined as a
TLCo80%), an abnormal diffusion capacity
(DLCOo75%) and/or the typical appearance of
fibrosis and ground glass pattern on high-resolution
computed tomography. The diagnosis of lupus
erythemathosus disseminatus,11 systemic sclero-
sis12 and Sj .ogren syndrome13 is according the
criteria of the American Rheumatism Association.
The criteria from Bohan et al.14 are used for the
diagnosis of dermato-polymyositis.
The diagnosis of hypersensitivity pneumonitis is
based on the presence of ILD with a suggestive
history and presentation15–17 including: exposure to
an agent that can induce hypersensitivity pneumo-
nitis, shortness of breath with partial clinical and
functional improvement upon avoidance of the
offending agent, a restrictive lung function pat-
tern, the presence of ground glass and/or fibrosis
pattern on high-resolution computed tomography
and the presence of a lymphocytosis in the BALF. If
the clinical, broncho-alveolar lavage and radiolo-
gical features are not convincing, a lung biopsy18 or
a specific challenge test is performed to strengthen
the diagnosis of hypersensitivity pneumonitis.19
An undefined form of fibrosis is a lung fibrosis for
which the origin or diagnosis not be defined and the
findings do not match with the criteria for IIP or for
other forms of ILD.
Routine investigations in the diagnostic
assessment of ILD
Lung function tests
Spirometry (VC, FEV1) was performed with a
pneumotachograph and integrator, TLC and RV
were obtained by body plethysmography. CO-
diffusing capacity or transferfactor (DLCO) was
measured with the single breath method. The lung
function tests were performed using standard
protocols, based on the guidelines and the refer-
ence values of the European Respiratory Society.20
Pulmonary histo-cytology
These investigations were performed selectively if
non-invasive evaluations were not diagnostic.
BALF was generally carried out in the right
middle lobe or lingula unless high-resolution com-
puted tomography advocated an other location.
Generally, 4 50ml sterile saline was instilled and
aspirated again by gentle manual suction. The
recovered fluid is immediately transported to the
laboratory for total and differential cell count.21 If
indicated a sampling was performed for microbio-
logic and for mineralogical analysis.
Generally, 4–8 peripheral transbronchiolo-alveo-
lar biopsies (TBB) were carried out and when
sarcoidosis was suspected bronchial biopsies were
taken in addition.
Finally if indicated an open lung biopsy (generally
2 cm3 in the middle lobe or lingula) or video-
assisted thoracoscopic lung biopsies (TLB) (up to 4
biopsies from different lobes) were performed for
histologic staining and microbiology.
Statistics
All results are presented as mean (SD) values. Cox
proportional hazard analysis with stepwise forward
method was performed to assess the association
between variables and all-cause mortality.
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Univariate Cox regression analysis was completed
to identify significant variables predicting survival
status. Variables which were significant by univari-
ate Cox regression analysis were taken as potential
predictors of survival and were used as covariates
in the forward stepwise multivariate Cox regression
analysis to identify independent predictors of
survival.
The relative risk ratio or hazard ratio (RR)
and 95% confidence interval for risk factors are
given, and Kaplan–Meier cumulative survival plots
were constructed. To quantify the RR on survival
between patients with or without the diagnosis of
UIP the risk ratio was calculated using Cox propor-
tional hazards analysis (with stepwise forward
method). To dichotomise each value the median
value of each variable was used, which made it
possible to calculate the relative risk ratio. To
dichotomise the variable ‘‘diagnosis’’ UIP or no-UIP
is used.
The probability of death within 5 years of
patients with ILD was calculated using the Ka-
plan–Meier method with a logistic regression
analysis technique.22
Results
Between 1990 and 1999 315 newly diagnosed ILD
were registered for this study. An overview of
diagnosis, percent biopsy proven, age and sex ratio
is presented in Table 1. SARC and IIP accounted
each for about 30% of the patients, CTD and HP
each for about 20%. Patients with SARC were most
often diagnosed in stage II. HP was by far most
often found in bird fanciers, especially in pigeon
breeders. Among CTD, rheumatoid arthritis and
systemic lupus erythematosus were most frequent,
followed by systemic sclerosis. The ILD tended in
general to show a male preponderance, except for
CTD. Smoking habits and therapy at diagnosis were
not retained in the study.
Table 2 shows the lung function and BALF data at
diagnosis for the whole group and subdivided in
those who died and who survived between 1990 and
1999. The volumes (VC, TLC) and DLCO were lowest
in IPF and highest in SARC. In general, those
who died had a more restrictive lung function and
a lower DLCO, and a higher percentage of
macrophages.
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Table 1 Overview of the different ILD and characteristics at diagnosis.
Diagnosis n % of total F/M Age % biopsy provenn
SARC
Stage I 22 7.0 1.0 43 (11) 36.4
Stage II 29 9.2 0.9 44 (12) 62.1
Stage III–IV 12 3.8 0.7 51 (14) 41.7
Not further specified 24 7.6 0.9 53 (13) 41.7
Subtotal 87 27.6 0.9 47 (13) 47.1
HP
Bird breeder disease 35 11.1 0.4 54 (16) 28.6
Other 15 4.8 0.9 48 (14) 60.0
Subtotal 50 15.9 0.5 52 (15) 38.0
CTD
RA 23 7.3 0.8 64 (12) 17.4
SLE 13 4.1 2.3 40 (15) 7.7
PSS 11 3.5 1.0 54 (13) 16.7
Other 9 2.9 1.3 64 (10) 33.3
Subtotal 56 17.8 1.1 57 (16) 17.5
IPF
UIP 64 20.3 0.5 65 (12) 32.8
Other IIP
DIP 12 3.8 2.0 51 (11) 41.7
NSIP 7 2.2 2.5 63 (10) 85.7
BOOP 10 3.2 1.5 55 (24) 50.0
Subtotal 93 29.5 0.7 62 (14) 39.8
Undefined form of fibrosis 29 9.2 0.9 65 (14) 24.1
All Total 315 100.0 0.8 56 (16) 36.1
nOnly the biopsies that were available for review are presented.
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The 315 patients were followed up for a mean of
37 (33) months, 75 (23.8%) died after 0.07–116.10
months (mean 27.31 (28.33), median 14.97
months). The mean follow up period for the 240
survivors was 40.54 (34.14) months (range 0.01–
137). The mean (95% confidence interval) survival
time of UIP was 43.25 (30.75–55.70) months, with a
median of 20.10 months, of undefined fibrosis 77.25
(57.68–96.86) months, of CTD 95.62 (79.58–111.66)
months, of SARC 107.99 (101.86–114.12) months, of
HP 101.50 (87.08–115.91) months and of other IIP
100.17 (82.67–117.67) months. A Kaplan Meier
analysis of the 6 different forms of ILD showed
significant difference in survival between the
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Table 2 Lung function and BALF data registered at diagnosis and divided in those who died and survived between
1990 and 1999.
Outcome Diagnosis Lung function (% pred) BALF
n VC TLC DLCO n Cell count
(104)
% Ma % Lym % Neu % Eos
Alive SARC 70 93 (20) 89 (20) 79 (20) 47 30 (28) 56 (23) 36 (24) 7 (13) 2 (6)
HP 43 84 (21) 84 (20) 53 (21) 30 71 (70) 37 (28) 56 (28) 6 (8) 1 (2)
CTD 34 80 (20) 80 (17) 49 (20) 16 38 (38) 57 (27) 21 (16) 20 (22) 2 (3)
IPF 19 75 (21) 69 (17) 41 (13) 14 25 (14) 45 (30) 20 (21) 27 (27) 7 (9)
IIP other 24 77 (23) 78 (18) 46 (17) 16 42 (39) 44 (27) 25 (18) 2 (3) 7 (10)
Undef. fibrosis 19 79 (21) 76 (15) 48 (22) 14 37 (34) 50 (31) 35 (31) 15 (21) 2 (2)
Died SARC 2 87 81 44 3 23 (27) 49 (24) 50 (25) 2 (1) 3 (6)
HP 4 51 (12) 67 (16) 35 (21) 3 75 53 (44) 32 (40) 16 (5) 0 (0)
CTD 16 71 (16) 66 (13) 40 (14) 7 17 (20) 65 (27) 26 (29) 7 (8) 3 (3)
IPF 33 61 (19) 59 (14) 34 (9) 23 25 (19) 67 (23) 12 (11) 14 (12) 7 (9)
IIP other 3 60 (16) 76 (22) 51 (14) 2 80 61 29 8 2
Undef. fibrosis 8 69 (22) 73 (21) 44 (17) 5 33 (38) 57 (37) 21 (31) 22 (34) 1 (1)
Total SARC 72 93 (20) 89 (20) 78 (20) 50 29 (28) 55 (23) 37 (24) 6 (12) 2 (6)
HP 47 81 (22) 83 (20) 51 (22) 33 71 (69) 38 (29) 53 (29) 7 (8) 1 (2)
CTD 50 77 (20) 75 (17) 46 (18) 23 61 (94) 59 (27) 23 (20) 16 (20) 2 (2)
IPF 52 66 (21) 63 (16) 37 (11) 37 25 (18) 58 (28) 15 (16) 19 (20) 7 (9)
IIP other 27 75 (23) 78 (18) 46 (17) 18 40 (38) 46 (27) 26 (18) 2 (2) 6 (10)
Undef. fibrosis 27 76 (21) 75 (16) 47 (21) 19 36 (34) 52 (32) 31 (31) 17 (24) 2 (2)
Figure 1 Kaplan–Meier analysis of the 6 different forms of ILD.
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different subgroups (Fig. 1). The mean survival 2
and 5 yr after diagnosis are schematically presented
(Fig. 1).
A multivariate Cox regression analysis with
stepwise forward method calculated the influence
on survival of diagnosis, lung function parameters,
sex, age at diagnosis, BALF findings and if the
diagnosis was based on lung biopsy or not. To
determine the interaction between the effects of
each of these variables in determining survival we
evaluated two variable models: the Cox regression
is analyzed with continues and with dichotomous
variables.
The regression analysis with continuous variables
was performed in four different stages. Taking age
at diagnosis, male sex, a biopsy proven diagnosis
and diagnosis (coding 1 for UIP, 2 for undefined
fibrosis, 3 for CTD, 4 for SARC, 5 for HP and 6 for
other IIP) into account, the risk (with 95% con-
fidence interval) for mortality in the 315 patients
with ILD was 1.02 (1.00–1.04) for age and 0.58
(0.48–0.70) for diagnosis. Taking diagnosis, age at
diagnosis, male sex, FVC (% predicted), FEV1
(% predicted), TLC (% predicted) and DLCO (%
predicted) in to account, the risk for mortality in
the 275 patients with ILD who received a lung
function at diagnosis was 0.71 (0.57–0.87) for type
of diagnosis, 0.10 (0.02–0.54) for TLC and 0.10
(0.01–0.72) for DLCO. Taking age at diagnosis, male
sex, diagnosis, total cell count, % macrophages, %
lymphocytes, % neutrophils and % eosinophils in
BALF into account, the risk for mortality in the 180
patients with ILD who received a BALF at diagnosis
was 1.06 (1.02–1.10) for age, 0.64 (0.47–0.86) for
diagnosis and 11.1 (2.54–48.48) for % macrophages.
The regression analysis with dichotomous vari-
ables is used to quantify the relative risk ratio on
survival. To dichotomise each value the median
value of each variable was used, which made it
possible to calculate the relative risk ratio. To
dichotomise the variable ‘‘diagnosis’’ UIP or no-UIP
is used (Table 3). The calculation was performed
using the same stepwise forward method as
described above. When using the calculation with
the Cox proportional hazards analysis (model with
dichotomous variables), an age of less than 66 year,
a diagnosis of an ILD that is not a UIP, a FVC of more
than 63% predicted and a % macrophages of less
than 63% in BALF indicated in this model a
reduction of mortality risk (Table 3).
Discussion
In the framework of a prospective registration
programme on ILD6,7 we compare in the present
study lung function and BALF characteristics in the
5 groups that are most frequently registered, and
we analyse the risk factors for mortality. We
recorded 315 prevalent cases between 1990 and
1999 in our division of respiratory medicine of the
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Table 3 Cox proportional hazards analysis of survival.
n Variable RR 95% CI
315 Ageo66 yr 0.49 0.30–0.79
Diagnosis of UIP 5.21 3.24–8.40
275 Ageo66 yr 0.36 0.20–0.65
Diagnosis of UIP 3.35 1.86–6.02
% FVCo63% 3.38 1.87–6.10
180 Ageo66 yr 0.29 0.13–0.61
Diagnosis of UIP 4.53 2.13–9.63
% Macrophageso63% 0.38 0.19–0.78
180 Ageo66 yr 0.23 0.12–0.46
Diagnosis of UIP 3.26 1.62–6.55
% FVCo63% 3.07 1.49–6.32
% Macrophageso63% 0.39 0.19–0.77
Each variable is dichotomized using their median value as cut-off. To dichotomize the variable ‘‘diagnosis’’ the study group is
divided in patients with the diagnosis of UIP (value of 1) and a group without UIP (value of 0). Since ‘‘diagnosis of UIP’’ is given
the value of 1, the variable is named diagnosis of UIP. All variables presented in this table are independent from the diagnosis.
The analysis is performed in four stages (see section on Results); RR, relative risk ratio, %95 CI: 95% confidence interval, UIP:
usual interstitial pneumonia, FVC: forced vital capacity.
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University Hospital in Leuven, i.e. sarcoidosis
(SARC, 27.6%), hypersensitivity pneumonitis (HP,
15.9%), lung fibrosis due to connective tissue
disease (CTD, 17.8%), idiopathic interstitial pneu-
monia (IIP, 29.5%) and undefined forms of fibrosis
(9.2%). In agreement with other studies, our study
confirms that IIP is predominantly a disease of
elderly man, with a mean age of 62 years and a
female to male ratio of 0.7. Patients who
present with the diagnosis of sarcoidosis tend to
be younger in comparison with the other ILD, and
ILD due to CTD is a female disease with a female to
male ratio of 1.1. The survival rates between the
different forms of ILD in our study were different,
with a mean survival after 5 yr of 91.6% in SARC,
84.1 in HP, 69.7% in CTD, 35.4% in IPF, 85.5% in
other IIP and 69.5% in undefined forms of lung
fibrosis.
The diagnosis of ILD is very complex, but these
diseases have clinically similar presentations with
increasing shortness of breath and shadowing on
the chest radiograph.5 The initial approach and the
assessment of the diagnosis of different forms of
ILD is rather similar: it involves a combination of
history taking and examination of the patient,
laboratory examinations, radiology (including high-
resolution computed tomography of the thorax),
pulmonary physiology, broncho-alveolar lavage,
and histological examination. The findings in our
study are interesting, because the variables used in
the diagnostic assessment can be used as predictor
of survival in the different ILD. We found that
higher age, the type of diagnosis, the severity of
functional restriction and a higher amount of
percentages of macrophages in BALF are indepen-
dent risk factors of mortality in the five most
common forms of ILD. The finding of a diagnosis of
IPF (UIP) and a FVCo63% predicted were the most
important independent risk factor, and these
findings increased the risk of mortality by more
than 3 fold. The amount of macrophages in BALF
and the age at diagnosis were also found to be an
important risk factors for the prognosis of the
disease. Gender, FVC, % lymphocytes and %
neutrophils in BALF were no significant relative
risk predictors.
This study has also some limitations: findings on
radiology and smoking history are not included in
the registration. Another limitation of this study is
that not all variables could be registered in all
patients: in some subjects who were referred to our
out-patient clinic the values at diagnosis and the
lung biopsy slides were not available for review. We
found in our study a higher proportion of patients
with DIP than with NSIP. A possible explanation is
that a patient with DIP is more likely to be referred
to our centre than a patient with NSIP, which could
be a possible recruiting bias in this study.
In summary, we provided data that are derived
from a large prospectively enrolled cohort showing
that age, type of ILD, BALF and physiologic findings
in the 5 most common forms of ILD influence
prognosis.
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